title: Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Sirma
authors.forename: Anneke
authors.initials: A
authors.lastname: Funk
authors.forename: Wolfram
authors.initials: W
authors.lastname: Gerlich
authors.forename: Oliver
authors.initials: O
authors.lastname: Schildgen
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D063065:Organophosphonates / Q000494:pharmacology*
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D063065:Organophosphonates; D019259:Lamivudine; C053001:adefovir; D000225:Adenine